Sava Infond d.o.o. Invests $656,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Sava Infond d.o.o. purchased a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,630 shares of the pharmaceutical company’s stock, valued at approximately $656,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Artisan Partners Limited Partnership grew its position in shares of Vertex Pharmaceuticals by 20.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 664,523 shares of the pharmaceutical company’s stock worth $267,603,000 after buying an additional 114,250 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Vertex Pharmaceuticals by 8.1% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 438,091 shares of the pharmaceutical company’s stock worth $178,351,000 after acquiring an additional 32,739 shares during the period. Ausdal Financial Partners Inc. boosted its holdings in Vertex Pharmaceuticals by 6.0% in the fourth quarter. Ausdal Financial Partners Inc. now owns 757 shares of the pharmaceutical company’s stock valued at $305,000 after acquiring an additional 43 shares in the last quarter. Murphy & Mullick Capital Management Corp purchased a new position in Vertex Pharmaceuticals during the 4th quarter valued at $1,313,000. Finally, Meiji Yasuda Asset Management Co Ltd. raised its holdings in Vertex Pharmaceuticals by 1.5% in the 4th quarter. Meiji Yasuda Asset Management Co Ltd. now owns 13,263 shares of the pharmaceutical company’s stock worth $5,341,000 after purchasing an additional 193 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Piper Sandler reduced their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. StockNews.com upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 11th. Bank of America lowered their target price on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research note on Thursday, December 19th. BMO Capital Markets set a $545.00 price target on Vertex Pharmaceuticals in a research note on Friday, January 31st. Finally, Royal Bank of Canada raised their price objective on Vertex Pharmaceuticals from $407.00 to $408.00 and gave the company a “sector perform” rating in a research report on Thursday, February 20th. Ten analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $506.70.

Vertex Pharmaceuticals Trading Down 1.7 %

NASDAQ:VRTX opened at $500.28 on Thursday. The company has a 50 day simple moving average of $473.33 and a two-hundred day simple moving average of $463.34. The company has a market cap of $128.47 billion, a PE ratio of -227.40, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP David Altshuler sold 3,231 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the sale, the executive vice president now directly owns 26,512 shares in the company, valued at $13,256,000. This represents a 10.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Ourania Tatsis sold 244 shares of Vertex Pharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now owns 67,695 shares in the company, valued at $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,315 shares of company stock worth $2,121,012 in the last quarter. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.